Oral Chemotherapy Market: Global Industry Analysis and Forecast (2022-2027) by Drug Class, Form, Distribution Channel, and Region

Oral Chemotherapy Market size was valued at US$ 1.35 Bn. in 2021 and the total Oral Chemotherapy revenue is expected to grow at 8.3% through 2022 to 2027, reaching nearly US$ 2.18 Bn.

Oral Chemotherapy Market Overview:

Governments have collaborated with businesses for decades to develop a variety of preventive and therapeutic measures, ranging from immunization and monitoring programs to surgical, pharmacological, radiological, and sociological therapies for cancer treatment. Even though these joint efforts in detection and treatment have led to significant gains in life expectancies, these statistics continue to vary significantly by type of tumor and geographic location. For example, in high-income nations, over 75% of children suffering from cancer will be cured, but in low and middle-income countries, just 11% of children treated for cancer will be cured. Global Oral Chemotherapy Market To know about the Research Methodology :- Request Free Sample Report Oncology is one of the few disciplines of medicine where the majority of patients are treated intravenously rather than orally. Numerous oral cancer medications have recently been certified, and many more are in the works. Oral chemotherapy appeals to patients because of its convenience and comfort of usage, especially in pain management. With a growing variety of oral medicines on the market, we may predict a substantial increase in the usage of oral chemotherapy in the forecast period. In this report, the Oral Chemotherapy market's growth reasons, as well as the market's many segments (Drug Class, Form, Distribution Channel, and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Oral Chemotherapy market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Oral Chemotherapy market situation.

Oral Chemotherapy Market Dynamics:

For companies in the pharma medication delivery industry, self-administration and residential care are likely to present considerable development prospects. This is mostly due to the growing older population since older people make up a sizable market for medication delivery systems for home healthcare. This aspect is also driving up demand for application-based injectable, pulmonary, topical, and epidermal medication treatments that are tailored to caretakers' and clients' needs. Governments in both rich and developing nations are advocating cost-cutting initiatives including lowering prescription subsidy costs and boosting the use of generic versions. Drugmakers throughout the globe are experiencing tremendous reducing costs challenges from government organizations, insurers, and patients. As a result of the decreasing price game, medication acceptance is increasing in emerging economies, where the need for low-cost treatments is strong. Several pharmaceutical businesses, however, are suffering as a result of this. This trend is supposed to continue in the future years, owing to ongoing pressure from insurance companies, medical insurance managers, and public and private users to lower pharma pricing due to worries about providing more innovative drugs to treat ailments. The key opportunity is that the expense of cancer drugs is typically addressed with a discussion of their advantages, specifically for emerging cancer therapies. Cancer treatments that target a specific molecular change have been produced in recent decades and may signify advancements in anticancer therapy. Some specialized medicines have been found to enhance clinical outcomes such as overall patient survival, and have revolutionized clinical outcomes for a variety of different cancers.

Oral Chemotherapy Market Segment Analysis:

By Form, the tablet segment dominated the market in 2020. It is expected to grow at a CAGR of 4.6% in the previously mentioned forecast period. This can be attributed to the rising consumption of prescription drugs, especially in the United States. Prescription medications cost almost $1.2 billion each day in the United States. Prescription medication expenditures in the United States are expected to climb 6.3% per year on aggregate over the next decade, according to the Center for Medicare and Medicaid Services. This is a source of considerable economic and social worry. Because the national government covers more than 41.5% of all retail prescription medicine expenditures, such hikes will put more strain on an already overburdened national budget. They are also expected to contribute to increased private medical insurance prices, resulting in higher expenditures for both companies and employees. Global Oral Chemotherapy Market This system provides little impetus for insurers and customers to choose low-cost substitutes to high-priced medications that may be just as effective. Medicaid compels insurers to cover all pharmaceuticals in certain protected classes nearly all cancer treatments, for example, and at least two drugs in every other class, leaving limited room for insurers to select lower-cost options.

Oral Chemotherapy Market Regional Insights:

The global market is being driven by rising demand for tablets and capsules for the treatment of cancer and increased government funding in research and development to enhance treatments. Because of increased healthcare spending and the incidence of cancers in the area, North America led the worldwide market in 2020, and this trend is expected to continue over the forecast period. During the projected period, the Asia Pacific oral chemotherapy market is expected to grow at a high CAGR of 4.5%. The oral chemotherapy market is expected to be driven by an increase in tobacco use, increased smoking, a fast increasing healthcare business, a rising patient population, and a significant rise in oncological anomalies in the region. In 2020, the APAC area is expected to have 9.2 million new cancer cases and 4.9 million cancer deaths, accounting for over half of the global cancer burden. In the region, China is responsible for 51.5 % of new cancer cases (4.2 million) and 54% of cancer fatalities (2.8 million). Although female breast cancer is the most often diagnosed cancer in virtually all Asian nations among women, there are significant variances in cancer profiles among males depending on the country. This is expected to positively influence the market in the region. The objective of the report is to present a comprehensive analysis of the Oral Chemotherapy market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Oral Chemotherapy market dynamics, structure by analyzing the market segments and projecting the Oral Chemotherapy market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Oral Chemotherapy market make the report investor’s guide.

Oral Chemotherapy Market Scope: Inquire before buying

Global Oral Chemotherapy Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US $ 1.35 Bn.
Forecast Period 2022 to 2027 CAGR: 8.3% Market Size in 2027: US $ 2.18 Bn.
Segments Covered: by Drug Class • Non-steroidal Aromatase Inhibitor • Protein Kinase Inhibitors • Anti-Androgens • Antineoplastic Agents • Alkalyting Agents
by Form • Tablets • Capsules • Liquids
by Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Drug Stores

Oral Chemotherapy Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Oral Chemotherapy Market Key Players

Amgen Inc • Pfizer • Sanofi S.A., • Novartis AG • Johnson and Johnson, • Merck and CO. F. Hoffman-La Roche AG • Celegene Corporation • Bristol-Myers Squibb • Eli Lily and Company • Exelixis • Clovis Oncology, Inc. • Jazz Pharmaceuticals, Inc. • Puma Biotechnology • AbbVie Inc. FAQs: 1. Which is the potential market for Oral Chemotherapy in terms of the region? Ans. North America led the worldwide market in 2020, and this trend is expected to continue over the forecast period. 2. What are the opportunities for new market entrants? Ans. The key opportunity is that the expense of cancer drugs is typically addressed with a discussion of their advantages. 3. What is expected to drive the growth of the Oral Chemotherapy market in the forecast period? Ans. Governments in both rich and developing nations are advocating cost-cutting initiatives including lowering prescription subsidy costs 4. What is the projected market size & growth rate of the Oral Chemotherapy Market? Ans. Oral Chemotherapy Market size was valued at US$ 1.35 Bn. in 2021 and the total Oral Chemotherapy revenue is expected to grow at 8.3% through 2022 to 2027, reaching nearly US$ 2.18 Bn. 5. What segments are covered in the Oral Chemotherapy Market report? Ans. The segments covered are Drug Class, Form, Distribution Channel, and Region.
1. Global Oral Chemotherapy Market: Research Methodology 2. Global Oral Chemotherapy Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Oral Chemotherapy Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Oral Chemotherapy Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Oral Chemotherapy Market Segmentation 4.1 Global Oral Chemotherapy Market, by Drug Class (2022-2027) • Non-steroidal Aromatase Inhibitor • Protein Kinase Inhibitors • Anti-Androgens • Antineoplastic Agents • Alkalyting Agents 4.2 Global Oral Chemotherapy Market, by Form (2022-2027) • Tablets • Capsules • Liquids 4.3 Global Oral Chemotherapy Market, by Distribution Channel (2022-2027) • Hospital Pharmacies • Retail Pharmacies • Drug Stores 5. North America Oral Chemotherapy Market(2022-2027) 5.1 Global Oral Chemotherapy Market, by Drug Class (2022-2027) • Non-steroidal Aromatase Inhibitor • Protein Kinase Inhibitors • Anti-Androgens • Antineoplastic Agents • Alkalyting Agents 5.2 Global Oral Chemotherapy Market, by Form (2022-2027) • Tablets • Capsules • Liquids 5.3 Global Oral Chemotherapy Market, by Distribution Channel (2022-2027) • Hospital Pharmacies • Retail Pharmacies • Drug Stores 5.4 North America Oral Chemotherapy Market, by Country (2022-2027) • United States • Canada • Mexico 6. Asia Pacific Oral Chemotherapy Market (2022-2027) 6.1. Asia Pacific Oral Chemotherapy Market, by Drug Class (2022-2027) 6.2. Asia Pacific Oral Chemotherapy Market, by Form (2022-2027) 6.2. Asia Pacific Oral Chemotherapy Market, by Distribution Channel (2022-2027) 6.2. Asia Pacific Oral Chemotherapy Market, by Country (2022-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Oral Chemotherapy Market (2022-2027) 7.1 Middle East and Africa Oral Chemotherapy Market, by Drug Class (2022-2027) 7.2. Middle East and Africa Oral Chemotherapy Market, by Form (2022-2027) 7.2. Middle East and Africa Oral Chemotherapy Market, by Distribution Channel (2022-2027) 7.4. Middle East and Africa Oral Chemotherapy Market, by Country (2022-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Oral Chemotherapy Market (2022-2027) 8.1. Latin America Oral Chemotherapy Market, by Drug Class (2022-2027) 8.2. Latin America Oral Chemotherapy Market, by Form (2022-2027) 8.2. Latin America Oral Chemotherapy Market, by Distribution Channel (2022-2027) 8.4. Latin America Oral Chemotherapy Market, by Country (2022-2027) • Brazil • Argentina • Rest Of Latin America 9. European Oral Chemotherapy Market (2022-2027) 9.1. European Oral Chemotherapy Market, by Drug Class (2022-2027) 9.2. European Oral Chemotherapy Market, by Form (2022-2027) 9.3. European Oral Chemotherapy Market, by Distribution Channel (2022-2027) 9.4. European Oral Chemotherapy Market, by Country (2022-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1 Amgen Inc 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 Pfizer 10.3 Sanofi S.A., 10.4 Novartis AG 10.5 Johnson and Johnson, 10.6 Merck and CO. F. Hoffman-La Roche AG 10.7 Celegene Corporation 10.8 Bristol-Myers Squibb 10.9 Eli Lily and Company 10.10 Exelixis 10.11 Clovis Oncology, Inc. 10.12 Jazz Pharmaceuticals, Inc. 10.13 Puma Biotechnology 10.14 AbbVie Inc.

About This Report

Report ID 98685
Category Healthcare
Published Date May 2021
Updated Date March 2022
Contact Us